<DOC>
	<DOCNO>NCT02246439</DOCNO>
	<brief_summary>Randomized , Placebo-Controlled , Phase 3 Trial RHB-102 ( BEKINDA ) ( Ondansetron 24 mg Bimodal Release Tablets ) Acute Gastroenteritis . The study evaluate safety efficacy RHB-102 ( BEKINDA ) treat Acute Gastroenteritis , compare placebo .</brief_summary>
	<brief_title>Randomized , Placebo-Controlled , Phase 3 Trial BEKINDA ( Ondansetron 24 mg Bimodal Release Tablets ) Vomiting Due Presumed Acute Gastroenteritis Gastritis ( The GUARD Study )</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Patients must vomit least twice 4 hour precede signing informed consent . A vomit episode define episode forceful expulsion stomach content . Retching patient already empty gastric content also consider vomit episode . A distinct episode characterize clear break vomit activity least 5 minute Emesis must nonbloody ( streaks blood presume due force retching allow ) All patient ( parent guardian patient &lt; age 18 ) must sign informed consent . Severe dehydration . Severe dehydration define two follow criterion presence decrease intake increase output due vomit diarrhea : Absent severely decrease urine output ; weak pulse and/or low blood pressure ; parch mucous membrane ; lethargy , confusion , delirium loss consciousness Signs symptom severe enough require immediate parenteral hydration and/or parenteral antiemetic medication Temperature &gt; 39.0 Likely etiology acute vomit diarrhea acute infectious toxic gastroenteritis gastritis . This include sign acute abdomen , may require surgical intervention Chemicallyinduced gastroenteritis , e.g. , alcohol , drug abuse irritant chemical Use within 24 hour study entry specific medication treatment nausea and/or vomiting , e.g. , 5HT3 antagonist phenothiazine , receipt IV fluid reason . Nonspecific gastrointestinal remedy , antacid , proton pump inhibitor homeopathic remedy , permit . Congestive heart failure , bradyarrhythmia ( baseline pulse &lt; 55/min ) , know long QT syndrome Patient know QTc prolongation &gt; 450 msec , note prior screen ECG , take medication know cause QT prolongation . Note : current list medication know cause QT prolongation see : http : //www.crediblemeds.org/healthcareproviders/druglist/ Use list show drug know risk TdP . Known underlying disease could affect assessment hydration modify outcome treatment , e.g. , renal failure , diabetes mellitus , liver disease , alcoholism . Patients type 2 dietcontrolled diabetes mellitus whose baseline blood glucose &lt; 200 may enter study Abdominal surgery within past 3 month History bariatric surgery bowel obstruction time Hypersensitivity know intolerance ondansetron 5HT3 antagonist Patient take apomorphine within 24 hour screen Patient previously participate study Patient participate another interventional clinical trial , indication , past 30 day For woman childbearing potential : document possible pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gastroenteritis</keyword>
	<keyword>Gastritis</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Nausea</keyword>
	<keyword>Diarrhea</keyword>
</DOC>